Literature DB >> 12715326

Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome.

J R Kerr1, V S Cunniffe, P Kelleher, R M Bernstein, I N Bruce.   

Abstract

Three cases of chronic fatigue syndrome (CFS) that followed acute parvovirus B19 infection were treated with a 5-day course of intravenous immunoglobulin (IVIG; 400 mg/kg per day), the only specific treatment for parvovirus B19 infection. We examined the influence of IVIG treatment on the production of cytokines and chemokines in individuals with CFS due to parvovirus B19. IVIG therapy led to clearance of parvovirus B19 viremia, resolution of symptoms, and improvement in physical and functional ability in all patients, as well as resolution of cytokine dysregulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715326     DOI: 10.1086/374666

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

Review 1.  The role of enterovirus in chronic fatigue syndrome.

Authors:  J K S Chia
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

2.  Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome.

Authors:  Andrea T White; Alan R Light; Ronald W Hughen; Lucinda Bateman; Thomas B Martins; Harry R Hill; Kathleen C Light
Journal:  Psychophysiology       Date:  2010-03-04       Impact factor: 4.016

Review 3.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 4.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Authors:  Ponraj Prabakaran; Zhongyu Zhu; Xiaodong Xiao; Arya Biragyn; Antony S Dimitrov; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

5.  Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis.

Authors:  Jonathan R Kerr
Journal:  Curr Rheumatol Rep       Date:  2008-12       Impact factor: 4.592

6.  Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Authors:  Dimiter S Dimitrov; James D Marks
Journal:  Methods Mol Biol       Date:  2009

Review 7.  Myalgic encephalomyelitis: International Consensus Criteria.

Authors:  B M Carruthers; M I van de Sande; K L De Meirleir; N G Klimas; G Broderick; T Mitchell; D Staines; A C P Powles; N Speight; R Vallings; L Bateman; B Baumgarten-Austrheim; D S Bell; N Carlo-Stella; J Chia; A Darragh; D Jo; D Lewis; A R Light; S Marshall-Gradisnik; I Mena; J A Mikovits; K Miwa; M Murovska; M L Pall; S Stevens
Journal:  J Intern Med       Date:  2011-08-22       Impact factor: 8.989

8.  Traditional chinese medicine for chronic fatigue syndrome.

Authors:  Rui Chen; Junji Moriya; Jun-Ichi Yamakawa; Takashi Takahashi; Tsugiyasu Kanda
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-27       Impact factor: 2.629

Review 9.  Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome.

Authors:  Jonathan R Kerr; David A J Tyrrell
Journal:  Curr Pain Headache Rep       Date:  2003-10

10.  Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis.

Authors:  Lihan Zhang; John Gough; David Christmas; Derek L Mattey; Selwyn C M Richards; Janice Main; Derek Enlander; David Honeybourne; Jon G Ayres; David J Nutt; Jonathan R Kerr
Journal:  J Clin Pathol       Date:  2009-12-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.